Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Santoleri, Fiorenzo ^a   Sorice, Paola ^a   Lasala, Ruggero ^a   Rizzo, Rosa Carmela ^a   Costantini, Alberto ^a  

^a Pescara General Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DEFINED DAILY DOSE; DRUG COST; DRUG DOSE; ECONOMIC EVALUATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRESCRIBED DAILY DOSE; RECEIVED DAILY DOSE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874250787     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056813     Document Type: Article

References (21)

1. Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, et al. (2011) Safe Handling of Oral Chemotherapeutic Agents in Clinical Practice: Recommendations From an International Pharmacy Panel. J OncolPract. Jan 7(1): 7-12.
2. Cassidy J, Douillard J-Y, Twelves C, McKendrick JJ, Scheithauer W, et al. (2006) Pharmacoeconomic analysis of adjuvant oral capecitabinevs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer. April 24 94(8): 1122-1129.
3. Bartel SB, (2007) Safe practices and financial considerations in using oral chemotherapeutic agents. Am J Health Syst Pharm. 2007 May 1 64(9Suppl 5): S8-S14.
4. Schwappach DL, Wernli M, (2010) Medication errors in chemotherapy: incidence, types and involvement of patients in prevention. A review of the literature. Eur J Cancer Care (Engl). May 19(3): 285-92.
5. Foulon V, Schöffski P, Wolter P, (2011) Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. ActaClin Belg. 2011 Mar-Apr 66(2): 85-96.
6. Gebbia V, Bellavia G, Ferraù F, Valerio MR (2011) Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents. Expert OpinDrugSaf. Dec 13.
7. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, et al. (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on Imatinib. Journal of clinicaloncology. 28: 2381-2388.
8. Zedler BK, Joyce A, Murrelle L, Kakad P, Harpe SE, (2011) Pharmacoepidemiologic analysis of the impact of calendar packaging on adherence to self-administered medications for long-term use. ClinTher. May 33(5): 581-97.
9. Zedler BK, Kakad P, Colilla S, Murrelle L, Shah NR, (2011) Does packaging with a calendar feature improve adherence to self-administered medication for long-term use? A systematicreview. ClinTher. Jan; 33 (1): 62-73.
10. Mahtani KR, Heneghan CJ, Glasziou PP, Perera R, (2011) Reminder packaging for improving adherence to self-administered long-term medications. Cochrane Database Syst Rev. Sep 7 9: CD005025.
11. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M, (2007) A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases. Value in Health, Jan-Feb 10(1): 3-12.
12. Mancini R (2012) Implementing a Standardized Pharmacist Assessment and Evaluating the Role of a Pharmacist in a Multidisciplinary Supportive Oncology Clinic. J SupportOncol. Jan20.
13. WHO Collaborating Centre for Drug Statistics Methodology (2011) Guidelines for ATC classification and DDD assignment 2012. Oslo.
14. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, et al. (2008) Medication compliance and persistence: terminology and definitions. Value Health. Jan-Feb 11(1): 44-7.
15. Halpern R, Agarwal S, Dembek C Borton L, Lopez-Bresnahan M, (2011) Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying terapie: a retrospective administrative claims analysis. Patient Prefer Adherence. Jan 20 5: 73-84.
16. Ho PM, Bryson CL, Rumsfeld JS, (2009) Medication Adherence: Its Importance in Cardiovascular Outomes. Circulation. Jun 16; 119 (23): 3028-35.
17. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM, (2008) The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. Jan 62(1): 76-87.
18. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, et al. (2007) A checklist for medication compliance and persistence studies using retrospective database. Value Health. Jan-Feb 10(1): 3-12.
19. ISPOR website. Medication Compliance and Persistence Special Interest Group (MCP): Accomplishments. Available: http://www.ispor.org/sigs/MCP_accomplishments.asp. International Society for Pharmacoeconomics & OucomesResearch (ISPOR).
20. Caetano PA, Lam JM, Morgan SG, (2006) Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization. Clin Ther. Sep; 28 (9): 1411-24.
21. Guérin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD, (2012) A restrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in real-world setting. Curr Med Res Opin. Jul 28(7): 1155-62.